Chief MD, Gangnam
Duk-ha Kim
The trust our patients have placed in this clinic was built on conviction and principle. We intend to hold to both, unchanged, through the next hundred years.
Seoul
Single-indication PN injectable guide
Vitaran is a polynucleotide (PN) medical device whose stated approved use in Korea names one treatment site — temporary improvement of crow’s feet — not a general facial-wrinkle or anti-aging claim.
Vitaran is a polynucleotide (PN) medical device manufactured by BR Pharm in Korea. BR Pharm’s own product record lists its device category, composition and item permit number, and states one approved use: temporary improvement of crow’s feet in adults.

Sources: BR Pharm — HP VITARAN product record (composition, device class, licence number and intended use)
Its listed material is polynucleotide sodium (PN). BR Pharm’s product record names PN as the composition and places the device in the tissue-restoration biomaterial category rather than a hyaluronic-acid filler category.
Sources: BR Pharm — HP VITARAN product record (composition, device class, licence number and intended use)
BR Pharm’s stated purpose is temporary improvement of crow’s feet — the fine lines at the outer corner of the eye — in adults. Two words in that sentence carry the whole scope: “crow’s feet” names the one site, and “temporary” rules out a permanent-result claim.
Sources: BR Pharm — HP VITARAN product record (composition, device class, licence number and intended use)
Because that is what BR Pharm’s product record states. It lists a single approved use tied to a single anatomical site, not a general facial-wrinkle indication covering multiple areas. Treat any area outside crow’s feet as outside this record until the clinic shows otherwise.
Sources: BR Pharm — HP VITARAN product record (composition, device class, licence number and intended use)
BR Pharm’s page classifies Vitaran as a medical device under the tissue-restoration biomaterial category, with item permit No. 23-784. Confirm that this exact product name and permit number match what is used in your treatment room.
Sources: BR Pharm — HP VITARAN product record (composition, device class, licence number and intended use)
BR Pharm states that Vitaran obtained CE MDR certification — the European Union’s medical device regulation framework — in 2026. This is a manufacturer-announced regulatory marking, separate from the Korean item permit above.
Sources: BR Pharm — HP VITARAN product record (composition, device class, licence number and intended use)
A 2026 Cureus systematic review pooled seven randomized trials of polynucleotides and polydeoxyribonucleotides across 183 participants — four in skin rejuvenation, one in surgical-scar prevention, two in wound healing. No serious adverse events were reported, but the authors describe the certainty of that evidence as low, citing small sample sizes and inconsistent trial protocols.
A 2025 Journal of Cosmetic Dermatology systematic review examined nine aesthetic-medicine studies of polynucleotides published between 2010 and 2024, covering 219 participants, and rated study quality as low to moderate. Wrinkle and skin-elasticity improvements were reported, but the review describes the evidence as lacking consistency, and some included studies disclosed authors’ ties to PN distributors.
No. Both systematic reviews evaluate the PN ingredient class across a range of products and studies; neither trial pool was assembled to test Vitaran specifically. A regulatory approval for one PN product does not turn ingredient-level review evidence into a product-specific trial of that product.
Sources: Cureus 2026;18(7):e112403 — systematic review of randomised trials of polynucleotides and polydeoxyribonucleotides (7 trials, 183 participants)J Cosmet Dermatol 2025;24(2):e16721 — systematic review of polynucleotides in aesthetic medicine (9 studies, 219 participants)
After assessment, the clinician decides whether the crow’s-feet area matches your goal and administers the injection within the site named in the approved use. Dose, injection points and schedule are clinical decisions that should be individualized rather than fixed to a standard package.
Sources: BR Pharm — HP VITARAN product record (composition, device class, licence number and intended use)
The crow’s-feet area sits close to the eye and its surrounding vasculature, which is a different anatomical setting from cheek, forehead or jawline injections. Ask the injecting clinician about their technique and precautions for this specific site before treatment.
BR Pharm’s own record calls the approved use a temporary improvement without giving a duration in months. The two PN systematic reviews behind this page — 7 randomized trials/183 participants and 9 aesthetic studies/219 participants — both rate the evidence as low to low-moderate certainty, cite small samples and inconsistent protocols, and were assembled to test the PN ingredient class rather than Vitaran itself, so neither supplies a Vitaran-specific duration figure. What actually decides how long a result holds is the treated depth, the dose used and how your own tissue responds, none of which this record states as a number. Ask the clinic how many sessions they plan for your case, what change they expect to see between sessions, and when they would reassess before recommending a repeat.
Sources: BR Pharm — HP VITARAN product record (composition, device class, licence number and intended use)Cureus 2026;18(7):e112403 — systematic review of randomised trials of polynucleotides and polydeoxyribonucleotides (7 trials, 183 participants)J Cosmet Dermatol 2025;24(2):e16721 — systematic review of polynucleotides in aesthetic medicine (9 studies, 219 participants)
Ask four things before booking: whether the proposed treatment area matches the stated approved use of crow’s feet; what precautions apply to injecting so close to the eye; whether the product name and item permit number shown to you match Vitaran’s own record; and what the clinic’s procedure is if you notice an adverse reaction.
Sources: BR Pharm — HP VITARAN product record (composition, device class, licence number and intended use)
No serious adverse events were reported across the seven randomized PN trials reviewed in Cureus, but that finding describes the PN ingredient pool, not a Vitaran-specific safety record. Ask the clinic to show Vitaran’s own instructions for use for a complete, product-specific reaction list.
Contact the treating clinic promptly for any unexpected, worsening or persistent symptom, and seek emergency care for a medical emergency. A site-specific warning-sign list should come from Vitaran’s own instructions for use rather than from another injectable’s list.
Vitaran shares its PN material with other polynucleotide products sold in Korea, but sharing an ingredient class is not the same as sharing an approval. Vitaran’s own record names one site — crow’s feet — while other PN products carry their own, separately approved uses. Confirm which product and which approved use apply before agreeing to any area.
Sources: BR Pharm — HP VITARAN product record (composition, device class, licence number and intended use)
That would sit outside the one approved use named in BR Pharm’s product record. Ask the clinic what basis it is offering for that area, since this record does not extend to it, and weigh that answer before consenting.
Sources: BR Pharm — HP VITARAN product record (composition, device class, licence number and intended use)
BR Pharm’s product record names a single treatment site for Vitaran. This table sets that stated scope next to what sits outside it, using only the wording in the record reviewed for this page.
| Scope | What the record states | What that means for you |
|---|---|---|
| Crow’s feet (outer eye corner) | Named as the approved use: temporary improvement of crow’s feet in adults. | This is the one site the reviewed record supports. |
| Any other facial or body area | Not named in the approved-use record reviewed for this page. | Ask the clinic what basis it offers before agreeing to treatment there. |
This table reflects only the wording found in BR Pharm’s product record; it is not a list of every area a clinic might propose.
Sources: BR Pharm — HP VITARAN product record (composition, device class, licence number and intended use)
Care is provided by the medical team at the branch you select. These clinicians lead the three branches linked from this guide; confirm the doctor assigned to your visit with that branch.
Chief MD, Gangnam
The trust our patients have placed in this clinic was built on conviction and principle. We intend to hold to both, unchanged, through the next hundred years.
Chief MD, Myeongdong
I want to be thinking about how the patient feels right up to the last moment of the procedure.
Chief MD, Hongdae
I will give my best with the attentiveness to catch even the smallest change.
Listed branch medical team — not a medical-review byline for this article.
Temporary improvement of crow’s feet — the fine lines at the outer corner of the eye — in adults. That is the one approved use named in BR Pharm’s own product record.
Polynucleotide sodium (PN). BR Pharm lists Vitaran under the tissue-restoration biomaterial device category with PN as its composition.
Not on the record reviewed for this page. BR Pharm’s product page names one site, and any other area falls outside that stated use.
It is registered as a medical device under the tissue-restoration biomaterial category, with item permit No. 23-784 on BR Pharm’s own product record.
BR Pharm states that Vitaran obtained CE MDR certification, the European Union’s medical device framework, in 2026.
A 2026 Cureus systematic review pooled seven randomized trials and 183 participants across skin rejuvenation, surgical-scar prevention and wound healing, reporting no serious adverse events but describing overall evidence certainty as low.
A 2025 Journal of Cosmetic Dermatology review examined nine studies and 219 participants, rating quality as low to moderate and noting inconsistent evidence for wrinkle and elasticity improvement; some study authors disclosed ties to PN distributors.
No. Both reviews assess the PN ingredient class across multiple products and studies; neither was designed to test Vitaran specifically, so the review findings describe the ingredient, not a Vitaran product trial.
No. Both use PN, but they are separate products with separate approvals. Rejuran’s stated purpose covers facial wrinkles more broadly across a multi-product lineup, while Vitaran’s record names one site, crow’s feet, in a single product.
Ask whether the proposed area matches the stated approved use of crow’s feet, what precautions apply to injecting near the eye, whether the product name and item permit number shown to you match Vitaran’s record, and what the clinic does if an adverse reaction occurs.
The crow’s-feet site sits close to the eye and its surrounding vasculature, a different setting from cheek or forehead injection. Ask the injecting clinician directly about their technique and precautions for this site.
That falls outside the one approved use named in BR Pharm’s product record. Ask the clinic what basis it is offering, since this record does not cover that area.
Contact the treating clinic promptly for any unexpected, worsening or persistent symptom, and seek emergency care for a medical emergency. Ask the clinic in advance for Vitaran’s own instructions for use rather than relying on another injectable’s reaction list.
Compare like for like: confirm the exact product name, the item permit number and what a session includes before comparing totals. This guide does not publish prices, and a lower total can reflect a different product or area.
We started in Gangnam in 2006 and the network now runs 17 branches across Korea. The line we work to is skin transformation woven into everyday life — care you can keep up with, rather than one dramatic change.
Free Consultation
There is no inquiry form on this page. Once you have picked a branch above, open that branch’s site or the official reservation center and choose a time yourself.